Identification of a human dermal macrophage population responsible for constitutive restraint of primary dermal fibroblast proliferation.
Primary human dermal cell suspensions prepared from the papillary dermis of keratomed skin strips were used to investigate the effect of indigenous dermal macrophages (HLA-DR+, CD11c+ CD11b+ CD1c- phagolysosome+) upon dermal fibroblast proliferation. Rapid dermal fibroblast expansion was induced upon immunomagnetic bead removal of CD11b+ or CD11c+ cells as well as by removal of more inclusive subsets contained within the DR+ population, but the removal of mast cells, endothelial cells, and CD1c+ dermal Langerhans cells from dermal cell suspensions failed to result in proliferation of the remaining cell subsets. Removal of 1B10+ fibroblasts from macrophage depleted (CD11b-) dermal cell suspensions essentially abrogated the unrestrained proliferation of the CD11b- dermal cells. Flow cytometric cell cycle analysis of cultured macrophage-depleted dermal cells confirmed that the unrestrained proliferating cells contain procollagen I+ as well as procollagen I- dermal fibroblasts. Inhibition of primary fibroblast expansion by adding a supernatant from unfractionated dermal cells suggested that a growth-inhibitory soluble activity of >30,000 kDa dominates the cytokine mixture released by unfractionated fresh dermal cells ex vivo. Inhibitory activity counterbalanced positive fibroblast growth- stimulatory cytokines released by dermal cells because neutralizing antibodies to insulin-like growth factor 1 and interleukin-1 beta resulted in decreased CD11b- dermal cell fibroblast proliferation. These data indicated an important role for dermal macrophages of the DR+ CD11b+ CD11c+ DC1c- phenotype in the normal homeostatic restraint of primary human dermal fibroblast proliferation.
Gonzalez-Ramos
A
A
Department of Dermatology, University of Michigan, Ann Arbor, USA.
Cooper
K D
KD
Hammerberg
C
C
D000328:Adult; D018845:CD11 Antigens / Q000032:analysis; D002455:Cell Division / Q000187:drug effects / Q000276:immunology; D005347:Fibroblasts / Q000166:cytology*; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D016898:Interferon-alpha / Q000494:pharmacology; D007375:Interleukin-1 / Q000494:pharmacology; D008264:Macrophages / Q000166:cytology* / Q000276:immunology; D012867:Skin / Q000166:cytology* / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D018845:CD11 Antigens; D006684:HLA-DR Antigens; D016898:Interferon-alpha; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D007334:Insulin-Like Growth Factor I